Partners Merck and Incyte are broadening their oncology alliance, moving into Phase III with a pair of treatments that use the body's natural defenses to fight cancer.
Ready for the lung cancer showdown between Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo? It's here, and way ahead of schedule.
California wants to cap drug prices, but Big Pharma isn't having it. Amid growing backlash over drug pricing, companies such as Johnson & Johnson and Bristol-Myers Squibb are funneling millions of dollars into stamping out a new proposal that would curb drug spending in the state.
In the face of hefty hep C competition from Gilead and AbbVie, can Daklinza profit from a set of niche uses?
Merck's Keytruda got a green light from the U.K.'s cost-effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.
Gilead and AbbVie may be dominating the hep C field with their next-gen combo treatments, but that doesn't mean there's no room for other companies to sneak in.
Bristol-Myers Squibb is the latest Big Pharma to pay up for bribery in China. The U.S.-based drugmaker agreed to a $14.7 million settlement with the Securities and Exchange Commission, to wrap up charges that its Chinese joint venture shelled out cash and other incentives to boost scripts for its drugs.
Bristol-Myers Squibb continued its immuno-therapy march today with a combo approval in melanoma. The pairing of its older med Yervoy and new PD-1 cancer-fighter Opdivo won the FDA's green light for patients with advanced melanoma and a particular genetic variation.
The deal makes ZS Bristol's primary vendor in the sector, allowing the Big Pharma to trim the list of vendors with which it works to analyze commercial data.
Checkpoint inhibitors Opdivo from Bristol-Myers Squibb and Keytruda from Merck are racing to rack up oncology indications in a range of cancer areas. But with Opdivo vaulting toward a kidney cancer approval, the collective group is about to claim its "first casualty" of the "paradigm shift" toward immuno-oncology drugs, in the words of Bernstein analyst Tim Anderson.